Payment overview · 2025
General Payments
$317,126.59
287 reported records · 16 companies
Healthcare provider profile · identity verified
Andrei M. Pop, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ELK GROVE VILLAGE, IL · NPI 1417156365
Verified facts
What the public records show
CMS Open Payments records show Andrei M. Pop, M.D. received $317,126.59 in general payments during 2025 across 287 reported records.
Edwards Lifesciences Corporation accounted for 98.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $312,151.87 | 98.4% | 231 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $3,312.66 | 1.0% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $628.29 | 0.2% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $175.94 | 0.1% | 4 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $169.49 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $157.42 | 0.1% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $146.02 | 0.1% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $141.66 | 0.0% | 16 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $44.00 | 0.0% | 2 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $43.02 | 0.0% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $39.01 | 0.0% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $35.34 | 0.0% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $22.26 | 0.0% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $22.02 | 0.0% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $20.21 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.38 | 0.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $225,437.50 | 49 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,937.50 | 3 |
| Travel and Lodging | $20,972.01 | 58 |
| Food and Beverage | $8,567.82 | 153 |
| Education | $1,211.76 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $275,126.84 | 81 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $11,307.18 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $4,523.80 | 41 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $3,432.04 | 5 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $3,432.04 | 5 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $1,310.66 | 10 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $798.44 | 3 | 2025 |
Source payment records
|
|||||
| Intracardiac Undivided Normalized: intracardiac undivided |
Device | Philips North America LLC | $628.29 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $157.42 | 9 | 2025 |
Source payment records
|
|||||
| TENDYNE Normalized: tendyne |
Device | Abbott Laboratories | $105.93 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $64.38 | 6 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| VENACURE 1470 PRO Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $39.01 | 1 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| TORCON NB Normalized: torcon nb |
Device | Cook Medical LLC | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| General - Embolics Normalized: general embolics |
Device | Boston Scientific Corporation | $18.26 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.38 | 3 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $14.53 | 3 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $12.52 | 1 | 2025 |
Source payment records
|
|||||
| Bulkamid Normalized: bulkamid |
Device | Boston Scientific Corporation | $10.32 | 1 | 2025 |
Source payment records
|
|||||
| AngioJet XMI Normalized: angiojet xmi |
Device | Boston Scientific Corporation | $8.35 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Steerable Access Solution Normalized: versacross steerable access solution |
Device | Boston Scientific Corporation | $7.69 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $5.61 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $5.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 134 |
| Carvedilol | Carvedilol | 290 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 49 |
| Ezetimibe | Ezetimibe | 146 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 35 |
| Lisinopril | Lisinopril | 119 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 33 |
| Eliquis | Apixaban | 96 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 23 |
| Chlorthalidone | Chlorthalidone | 74 | 23 |
| Furosemide | Furosemide | 61 | 25 |
| Warfarin Sodium | Warfarin Sodium | 60 | 13 |
| Losartan Potassium | Losartan Potassium | 57 | 21 |
| Enalapril Maleate | Enalapril Maleate | 41 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 16 |
| Cilostazol | Cilostazol | 27 | 11 |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317,126.59 · 287 records | Edwards Lifesciences Corporation | ARTIX MT, AVVIGO Guidance System, AngioJet XMI, Barostim Neo System, BioMimics 3D Vascular Stent System, Bulkamid, CARDIVA VASCADE MVP VVCS 6-12F, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELUVIA, EVOQUE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARAPULSE, FLOWTRIEVER CATHETER, S, GORE VIABAHN VBX Balloon Expandable Endo, General - Embolics, Intracardiac Undivided, LEQVIO, LifeVest, MANTA, PASCAL, SAPIEN 3 Ultra RESILIA, TENDYNE, TORCON NB, TRICLIP, VENACURE 1470 PRO, VersaCross Steerable Access Solution, WATCHMAN FLX, XIENCE SKYPOINT, ZENITH SPIRAL-Z | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error